Explore tweets tagged as #ISPY2
@MarcosLepeMD
Marcos Lepe, MD
9 years
Dr van 't Veer: ISPY2 Trial focuses on PARPinh #ASCyto2016 #ASC2016
0
7
5
@MAGICALSPEC
MAGICAL SPEC @ 11月22日(土)ワンマンライブ開催
3 years
【本日開催】 渋谷O-Crestにて 「MAGICAL SPEC 無銭ワンマン〜マジスペIDORISE!! FESTIVAL 2023感謝祭〜」 ⏰開場 16:30 / 開演 17:00 🎫無料(+1d) ※当日受付あり 「Weekday session〜 MAGICAL SPEC × iSPY2マンライブ 〜」 ⏰開場 19:00 / 開演 19:30 🎫当日券あり ※ANNAは前物販となります
1
14
65
@ispy_official
iSPY【Official】
3 years
本日はWeekday session〜MAGICAL SPEC × iSPY2マンライブ〜お越し頂きありがとうございました!✨ #マジスペ さん本日は2マンお呼び頂きありがとうございました❣️ これからも是非仲良くして下さい🥰 次のiSPYは3/16(木)19:15~【iSPY ×カメイドクロック無料定期公演】です!!🐢
0
2
55
@emilykatehayes
Emily
8 years
#ASCO17 Merck's Keytruda passes test in ISPY2 neoadjuvant breast cancer study, high risk types
0
13
8
@stolaney1
Sara Tolaney
1 year
ISPY2.2 Dato-DXd+ durva, results of blocks A thru C: pCR 50% n=106 (n=42 HR+, n=64 TNBC) pCR 62% TNBC, 79% Immune + HR-HER2-Immune-DPD- :met graduation criteria @OncoAlert #ESMO24
1
11
23
@stolaney1
Sara Tolaney
4 years
ISPY2: THP + tucatinib with unacceptable g3-4 tox making it not feasible, unfortunately. @OncoAlert #bcsm #SABCS21
0
14
23
@hoperugo
Hope Rugo
8 years
Rita Nanda presents fabulous ISPY2 pembro data! Bravo. #ASC017
0
5
5
@hoperugo
Hope Rugo
8 years
Pembrolizumab graduates in all ISPY2 arms with 3x increase in pCR in TN! #ASCO17
1
8
12
@kokoro__hagita
萩田こころ
3 years
Weekday session〜MAGICAL SPEC × iSPY2マンライブ〜 ありがとうございました🫧 んー!楽しかったー!! マジスペさんとっても元気で可愛くて口角ずっと上がってた👼🏻♡ 呼んでいただきありがとうございます! またすぐ会えますように…✨ これからも仲良くしてください🫶🏻
10
13
123
@DrJudyBoughey
Judy Boughey
1 year
Data from ispy2 shows IM lymphadenopathy in patients treated with neoadjuvant chemotherapy does not negatively impact outcome. #asbrs24@ISPY2trial@DrMaraPiltin⁩ ⁦@MayoClinicSurg⁩ ⁦@MayoCancerCare
1
5
33
@DrHBurstein
Harold J. Burstein, MD, PhD, FASCO
9 years
Ispy2 study shows Kadcyla + Perjeta better than taxol/Herceptin as neoadj therapy in Her2+ breast cancer @AACR
0
8
2
@hoperugo
Hope Rugo
8 years
At ASCO with humanitarian awardee and co ISPY2 chaperone Funmi Olopade. Remarkable woman I am proud to know #ASCO17
0
1
11
@dr_coops
Matt Cooperberg
5 years
Every time I get to hear @DrLauraEsserman talk about #ISPY2 I wish even more we could just copy & paste for prostate cancer. This truly is a transformative framework, amazing work. @PCFnews #PCFRetreat
2
8
27
@TraumaDocSF
Andre Campbell, MD, FACS, FACP, FCCM, MAMSE, FCBC
2 years
Great talk by Dr Rita Muktar on the treatment or breast cancer. Less is just as good as more from the ISpy2 data set. @UCSFSurgery
0
2
24
@DrSGraff
Stephanie Graff, MD, FACP, FASCO
8 years
ISPY2 pembrolizumab data shows tripling of ypCR in all her2 negative subsets! (Triple neg and ER+) #ASCO17 #bcsm
0
2
2
@DrJudyBoughey
Judy Boughey
2 years
Breast conserving surgery has similar locoregional recurrence to mastectomy after neoadjuvant chemotherapy - excellent presentation from Dr Rita Mukhtar showing data from ISPY2 clinical trial @ISPY2trial #ASA2023
1
9
40
@DrJudyBoughey
Judy Boughey
2 years
#asbs24 presentation by Kayla Switalla on the ISPY2 trial demonstrating increasing use of clip placement in patients with positive nodes. Data demonstrates that clip placement is beneficial and increases use of TAD ⁦@ISPY2trial
1
3
22
@oncology_bg
Bishal Gyawali, MD, PhD, FASCO
9 years
My latest blog @ecancer on the adaptive randomization and #ISPY2 trials. https://t.co/u1Boqwvi97. @VincentRK @pash22
1
10
13
@to_be_elizabeth
Elisabetta Bonzano MD, PhD
1 year
Is More Better? Customizing Systemic Therapy for High-Risk, Nonmetastatic Breast Cancer ➡️ Outstanding discussion 🔛 PEARLY trial, A-BRAVE trial and ISPY2.2 trial by @JavierCortesMD 👏🏻👏🏻👏🏻 #ASCO24 @OncoAlert #BreastCancer
0
7
12